Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors

Next Previous
Trial Profile

Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Pembrolizumab (Primary) ; Rinatabart sesutecan (Primary)
  • Indications Advanced breast cancer; Carcinoma; Endometrial cancer; Fallopian tube cancer; HER2 negative breast cancer; Male breast cancer; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Triple negative breast cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms GCT1184-01/PRO1184-001; RAINFOL-01
  • Sponsors ProfoundBio

Most Recent Events

  • 02 Jun 2025 According to a Genmab media release, new result data from cohort B2 of the Phase 1/2 RAINFOL-01 trial was presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
  • 02 Jun 2025 Results from cohort B2 of the Phase 1/2 RAINFOL-01 trial published in the Genmab Media Release.
  • 20 Apr 2025 Planned number of patients changed from 404 to 529.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top